PMID- 15645422
OWN - NLM
STAT- MEDLINE
DCOM- 20050516
LR  - 20160303
IS  - 0020-7136 (Print)
IS  - 0020-7136 (Linking)
VI  - 114
IP  - 6
DP  - 2005 May 10
TI  - Anti-tumor efficacy of the nucleoside analog 
      1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl) cytosine (4'-thio-FAC) in 
      human pancreatic and ovarian tumor xenograft models.
PG  - 1002-9
AB  - 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl) cytosine (4'-thio-FAC) is a 
      deoxycytidine analog that has been shown previously to have impressive 
      anti-proliferative and cytotoxic effects in vitro and in vivo toward colorectal 
      and gastric tumors. In our present studies, the pharmacokinetic behavior in nude 
      mice and the effectiveness of 4'-thio-FAC against human pancreatic and ovarian 
      tumor growth were assessed in comparison with standard chemotherapeutic agents. 
      Potent in vitro anti-proliferative effects were observed against pancreatic 
      (Capan-1, MIA-PaCa-2, BxPC-3) and ovarian (SK-OV-3, OVCAR-3, ES-2) cancer cell 
      lines with IC(50) of 0.01-0.2 microM. In vivo anti-tumor activity was evaluated 
      in nude mice bearing subcutaneously (s.c.) implanted human pancreatic tumor 
      xenografts or intraperitoneally (i.p.) disseminated human ovarian xenografted 
      tumors. Oral daily administration of 4'-thio-FAC for 8-10 days significantly 
      inhibited the growth of gemcitabine-resistant BxPC-3 pancreatic tumors and 
      induced regression of gemcitabine-refractory Capan-1 tumors. 4'-Thio-FAC was also 
      a highly effective inhibitor of ovarian peritoneal carcinomatosis. In the SK-OV-3 
      and ES-2 ovarian cancer models, 4'-thio-FAC prolonged survival to a greater 
      extent than that observed with gemcitabine. Furthermore, the superiority of 
      4'-thio-FAC to carboplatin and paclitaxel was demonstrated in the ES-2 clear cell 
      ovarian carcinoma model. Studies provide evidence that 4'-thio-FAC is a promising 
      new alternative to gemcitabine and other chemotherapeutic drugs in the treatment 
      of a variety of tumor indications, including pancreatic and ovarian carcinoma.
FAU - Zajchowski, Deborah A
AU  - Zajchowski DA
AD  - Department of Cancer Research, Berlex Biosciences, Richmond, CA 97808, USA. 
      Deb_zajchowski@berlex.com
FAU - Biroc, Sandra L
AU  - Biroc SL
FAU - Liu, Hsaio-Lai
AU  - Liu HL
FAU - Chesney, Steven K
AU  - Chesney SK
FAU - Hoffmann, Jens
AU  - Hoffmann J
FAU - Bauman, John
AU  - Bauman J
FAU - Kirkland, Thomas
AU  - Kirkland T
FAU - Subramanyam, Babu
AU  - Subramanyam B
FAU - Shen, Jun
AU  - Shen J
FAU - Ho, Elena
AU  - Ho E
FAU - Tseng, Jih-Lie
AU  - Tseng JL
FAU - Dinter, Harald
AU  - Dinter H
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (1-(2-deoxy-2-fluoro-4-thio-arabinofuranosyl)cytosine)
RN  - 04079A1RDZ (Cytarabine)
SB  - IM
MH  - Animals
MH  - Carcinoma/*drug therapy/pathology/veterinary
MH  - Cytarabine/*analogs & derivatives/*pharmacology
MH  - Disease Models, Animal
MH  - Female
MH  - Mice
MH  - Mice, Nude
MH  - Ovarian Neoplasms/*drug therapy/pathology/veterinary
MH  - Pancreatic Neoplasms/*drug therapy/pathology/veterinary
MH  - Transplantation, Heterologous
MH  - Tumor Cells, Cultured
EDAT- 2005/01/13 09:00
MHDA- 2005/05/17 09:00
CRDT- 2005/01/13 09:00
PHST- 2005/01/13 09:00 [pubmed]
PHST- 2005/05/17 09:00 [medline]
PHST- 2005/01/13 09:00 [entrez]
AID - 10.1002/ijc.20835 [doi]
PST - ppublish
SO  - Int J Cancer. 2005 May 10;114(6):1002-9. doi: 10.1002/ijc.20835.